From: (SANTE) on behalf of (SANTE)

Sent: 04 December 2020 13:59

To:
Cc: (SANTE); (SANTE)

RE: invitation to present EU Pharmaceutical Strategy at PPTA EU Board

Dear

Subject:

Thank you very much for your email.

We have been informed that you have also been in contact with B4 unit on the below issue.

We will of course stay in touch for future possibilities.

Kind regards,



European Commission

Health and Food Safety Directorate General (SANTE) Unit B5 Medicines-policy, authorisation and monitoring

B-1049 Brussels, Belgium

Subject: RE: invitation to present EU Pharmaceutical Strategy at PPTA EU Board

Dear ,

Thank you very much for your feedback.

We off course understand the busy schedules these days with amounts of workload ongoing. If we can be of any assistance, for example by contributing as stakeholders to the study concerning the root causes of shortages, we are happy to support. As you might know, our industry is not represented by EFPIA as we are in a very unique situation where our starting materials for medicines in human plasma. We are from time to time forgotten in our niche, if I may say so. However we have 300,000 patients in Europe relying on plasma-derived medicines.

On the other side, I hope I may take the liberty to come back later on, when agendas are more convenient, with an invitation to participate to a PPTA Board meeting.

Kind Regards,



Plasma and Blood Donors Save Lives

Visit www.pptaglobal.org/COVID19 to learn more

 $\label{thm:continuous} \mbox{Visit} \ \underline{\mbox{www.donatingplasma.org}} \ \mbox{to find a donation center near you}$



From:	@ec.europa.eu		@ec.europ	a.eu> On Behalf Of		
	@ec.europa.eu					
Sent: Thursday, 26 November 2020 19:18						
To:			>	_		
Cc:		>;		@ec.europa.eu;		
	<u>@ec.europa.eu</u>					
Subject: RE: invitation to present EU Pharmaceutical Strategy at PPTA EU Board						
Dear						
On behalf of invitation.		, we would li	ke to thank	you for your email and for the		

Unfortunately, due to very busy schedules in this period of time we would have to kindly decline our participation.

We wish you though every success with the meeting.

Kind regards,



Unit B5 Medicines-policy, authorisation and monitoring

B-1049 Brussels, Belgium

From:		>			
Sent: Tuesday, Nov	vember 17, 2020 1	2:00 PM			
To:	(SANTE)	@ec.europa.eu>;			
(SANTE)	@ec.europa.eu>				
Cc:					
Subject: invitation to present EU Pharmaceutical Strategy at PPTA EU Board					
Dear	,				
·					

I hope you are doing well in these exceptional times.

I understand you must be very occupied with the finalization of the EU Pharmaceutical Strategy, which is planned to be presented very shortly. We are looking forward to the results.

I would like to kindly invite you to have a dialogue with our Board on the Pharmaceutical strategy. We would be honored if one of you would be able to participate to our upcoming PPTA EU Board meeting (1 December 14h30 – 16h00) for 30 minutes for a short presentation and Q&A.

. Attached you can find for your information our submission to the public consultation.

I understand the busy times, and the short notice. Yet, I'm looking forward to your, hopefully positive, feedback.


Kind Regards,



1200 Brussels
Belgium
Tel.: +32
Mobile: +32
@pptaglobal.org
www.pptaglobal.org
Follow us on

Plasma and Blood Donors Save Lives

Visit www.pptaglobal.org/COVID19 to learn more
Visit www.donatingplasma.org to find a donation center near you



Message from PPTA Email Security System This email is from an external system. Please do not attempt to open any attachments or click on any links within this email if there is any doubt about the validity of the sender or the content within the email. When in doubt it's best to delete the email.